---
created: 2025-04-13
updated: 2025-04-13T10:52
id: m_]_.1Wza[
specialty: immuno
specialty_id: 101
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::alemtuzumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::20-alemtuzumab
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::07-immunology
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::17-hem/onc-pharm::rituximab-bevacizumab-alemtuzumab-cetuximab-panitumumab-trastuzmab
  - "source/ak-step1-v11:": 
  - theme/pixorize::01-immunology::07-leukemias-&-lymphomas::04-cll
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::immunology-&-biochemistry-pharmacology::immuno-suppressives::general-immunotherapy
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
Alemtuzumab is primarily used to treat **Chronic Lymphocytic Leukemia** and **Multiple Sclerosis**

---

# Answer
